CSL Limited enters into License and Option Agreement with Wyeth for its Iscomatrix® Adjuvant Technology

CSL Limited enters into License and Option Agreement with Wyeth for its Iscomatrix® Adjuvant Technology

Melbourne, Australia — 14/12/2006

CSL Limited, Australia’s leading biopharmaceutical company, today announced that it has signed a worldwide license and option agreement with Wyeth (NYSE: WYE), granting certain rights and options to Wyeth for the use of CSL’s ISCOMATRIX® adjuvant in a number of Wyeth’s investigational vaccine programs.

“This agreement further endorses the broad use of ISCOMATRIX® adjuvant in novel vaccine development programs” said Dr Andrew Cuthbertson, Chief Scientific Officer at CSL. “We are delighted to work with Wyeth, a company with a strong commitment to development of innovative vaccines in the human health arena, and to add them to our existing ISCOMATRIX® adjuvant partners.”

Under the terms of the agreement CSL could receive an upfront, options and milestone payments that total up to more than US$90m as well as, royalties on future product sales. CSL will supply all of Wyeth’s requirements for ISCOMATRIX® adjuvant for development and commercialisation. Other financial terms were not disclosed.

About ISCOMATRIX® Adjuvant
An adjuvant is used to improve or modify the body’s immune response to an antigen. Adjuvants play an important role in the development of vaccines, by potentially generating broader, more potent and durable immune responses.

The ISCOMATRIX® adjuvant is a saponin-based adjuvant with both antigen delivery and immunomodulatory properties making it ideally suited for use in the development of a new generation of human vaccines. ISCOMATRIX® vaccines have been shown to be safe and immunogenic in human clinical trials with induction of strong and long-lived humoral and cellular immune response.

CSL has a number of license and collaborative agreements in place with global vaccine and biotechnology companies for its ISCOMATRIX® adjuvant. These companies include Merck & Co. Inc. and Chiron Corporation (part of the Novartis group of companies). CSL also uses ISCOMATRIX® adjuvant in its own vaccine development programs.

Download this release: PDF icon CSL Limited enters into License and Option Agreement with Wyeth for its Iscomatrix® Adjuvant Technology

Media Contact:
Dr Rachel David
CSL Limited
Director of Public Affairs
Phone: 0401 775 779

Analysts Contact:
Mark Dehring
CSL Limited
Director of Investor Relations
Phone: 0423 780 328
© 2016 CSL Limited